We are joined by Alessandra Tedeschi at EHA 2019 to discuss her presentation on the five-year follow-up of patients receiving ibrutinib for first-line treatment of chronic lymphocytic leukemia (CLL).
1. How does ibrutinib fit into the treatment paradigm for chronic lymphocytic leukemia? (0:05)
2. What were the major findings of the long-term follow-up of the RESONATE-2 study? (0:27)
3. Which patient subgroups were most likely to experience durable responses? (1:09)
4. What is the long-term safety profile of ibrutinib? (1:38)
5. What are the treatment options for patients who discontinue ibrutinib therapy? (2:13)
Alessandra Tedeschi has no conflicts of interest to declare in relation to this video.
Filmed at the European Hematology Association (EHA) 24th congress 2019, Amsterdam, Netherlands.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Leukaemia
PART ONE: Nicholas Short, EHA 2022: Ponatinib and blinatumomab in patients with PH+ALL: Results of a phase II study
In Part One of this video interview, Prof Nicholas Short (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) discusses his phase II trial looking at ponatinib and blinatumomab for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia. A total of 55 patients were treated and the combination therapy showed complete molecular response. These […]
PART TWO: Nicholas Short, EHA 2022: Ponatinib and blinatumomab in patients with PH+ALL: Results of a phase II study
In Part Two of this video interview, Prof Nicholas Short (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) summaries the rationale, design and eligibility criteria of his phase II trial looking at ponatinib and blinatumomab for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia, and summarizes the key take-home conclusions. A total of […]
Jorge Cortes, EHA 2022: Magrolimab plus azacitidine in the patients with AML and HR MDS
Professor Jorge Cortes (Georgia Cancer Center, Augusta, GA, USA) summarizes two more important abstracts from the 27th Congress of the European Hematology Association (EHA) looking at magrolimab, an antibody blocking CD47, “don’t eat me” signal on cancer cells. The first is a phase III trial (NCT05079230) assessing magrolimab in combination with venetoclax and azacitidine in […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!